Table 1 Clinical characteristics of study population according to CHA2DS2-VASC
Variable | CHA2DS2-VASc Score | p-value | ||
|---|---|---|---|---|
low risk (1 point, n = 64) | intermediate risk (2–3 points, n = 135) | high risk (≥4 points, n = 40) | ||
Age (years), mean (SD) | 53.0 ± 7.5 | 59.1 ± 6.4 | 67.9 ± 7.9 | P<0.001 |
Gender (female), n(%) | 0 | 63 (47.4) | 19 (47.5) | P<0.001 |
Body mass index (Kg/m2) | 25.3 ± 1.8 | 24.4 ± 2.9 | 24.3 ± 2.6 | 0.04 |
Diabetes Mellitus, n(%) | 0 | 20 (14.8) | 20 (50.0) | P<0.001 |
Hypertension, n(%) | 0 | 34 (25.2) | 27 (67.5) | P<0.001 |
Stroke history, n(%) | 0 | 2 (1.5) | 6 (15.0) | P<0.001 |
Current smoker, n(%) | 17 (26.6) | 45 (33.3) | 8 (20.0) | 0.23 |
Previous MI, n(%) | 19 (29.2) | 46 (34.1) | 11 (25.5) | 0.67 |
Systolic blood pressure (mmHg) | 119.1 ± 13.7 | 121.8 ± 12.1 | 124.6 ± 14.2 | 0.28 |
Diastolic blood pressure (mmHg) | 74.7 ± 10.0 | 74.2 ± 9.3 | 72.4 ± 5.8 | 0.015 |
Pulse pressure (mmHg) | 44.4 ± 10.2 | 47.6 ± 9.7 | 52.2 ± 12.2 | 0.001 |
LVEF | 0.51 ± 0.04 | 0.45 ± 0.06 | 0.43 ± 0.04 | P<0.01 |
NYHA 2–3 on admision | 0 | 20 (14.8) | 17 (42.5) | P<0.01 |
Total Cholesterol (mmol/L) | 4.2 ± 1.0 | 4.3 ± 1.1 | 4.3 ± 0.9 | 0.70 |
LDL-C (mmol/L) | 2.6 ± 0.6 | 2.5 ± 0.6 | 2.7 ± 0.6 | 0.23 |
HDL-C (mmol/L) | 1.1 ± 0.3 | 1.1 ± 0.3 | 1.2 ± 0.4 | 0.25 |
Triglyceride (mmol/L) | 1.6 ± 1.2 | 1.5 ± 1.3 | 1.3 ± 0.8 | 0.59 |
Fasting Glucose (mmol/L) | 5.3 ± 0.5 | 5.5 ± 0.8 | 5.8 ± 1.0 | 0.027 |
eGFR baseline (ml/min/1.73m2) | 102.0 ± 13.8 | 92.8 ± 17.0 | 89.5 ± 17.6 | P<0.001 |
eGFR after PCI (ml/min/1.73m2) | 98.4 ± 14.2 | 87.4 ± 19.5 | 76.2 ± 21.3 | P<0.001 |
First Day Creatinine (μmol/l) | 68.8 ± 19.2 | 69.5 ± 16.9 | 65.0 ± 17.6 | 0.37 |
Uric acid (μmol/l) | 330.3 ± 69.9 | 330.8 ± 69.8 | 336.1 ± 75.6 | 0.90 |
Total amount of conrrast (ml) | 181.8 ± 63.5 | 241.8 ± 104.0 | 320.3 ± 92.5 | P<0.001 |
Total time of procedure (min) | 74.4 ± 45.6 | 96.1 ± 47.7 | 129.7 ± 51.6 | P<0.001 |
The retrograde approach, n(%) | 14 (21.5) | 29 (21.5) | 14 (35.0) | 0.19 |
Transradial + transfemoral approach, n(%) | 21 (32.8) | 42 (31.1) | 17 (42.5) | 0.40 |
IABP, n(%) | 4 (6.3) | 6 (4.4) | 7 (17.5) | 0.02 |
IVUS, n(%) | 4 (6.3) | 9 (6.7) | 5 (12.5) | 0.42 |
Stent number | 1.9 ± 0.3 | 2.3 ± 0.6 | 2.6 ± 1.1 | P<0.001 |
Glycoprotein IIb/IIIa receptor inhibitor, n(%) | 12 (18.8) | 24 (17.8) | 13 (32.5) | 0.12 |
CIN | 4 (6.3) | 20 (14.8) | 15 (37.5) | P<0.001 |